Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon enters into a corporate integrity agreement with HHS Inspector General, which likely will be in line with its existing compliance program, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges
Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs
Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges
Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs
Cephalon Settles Off-Label Charges With $425 Million Payout
Attorneys general in Connecticut and Massachusetts get another $6.85 million.